Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

BACKGROUND: Detecting epidermal growth factor receptor (EGFR) activating mutations in plasma could guide EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment for advanced non-small cell lung cancer (NSCLC). However, dynamic quantitative changes of plasma EGFR mutations during the whole course of EGFR...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Hematol Oncol
Hlavní autoři: Zhou, Qing, Yang, Jin-Ji, Chen, Zhi-Hong, Zhang, Xu-Chao, Yan, Hong-Hong, Xu, Chong-Rui, Su, Jian, Chen, Hua-Jun, Tu, Hai-Yan, Zhong, Wen-Zhao, Yang, Xue-Ning, Wu, Yi-Long
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5020532/
https://ncbi.nlm.nih.gov/pubmed/27619632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0316-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky